Traders should monitor enrollment progress and safety signals ahead of the Q4 2026 topline data readout, which could serve as a major value inflection point. Positive durability data could position icovamenib as a first-in-class disease-modifying therapy in T2D, justifying premium valuation in a high-unmet-need population.
Price Chart
Executive Summary
Biomea Fusion announced the first patient dosed in two Phase II trials (COVALENT-211 and COVALENT-212) evaluating icovamenib in type 2 diabetes patients with high unmet need, including insulin-deficient patients and those uncontrolled on GLP-1 therapies. Topline data from both studies are expected in Q4 2026, marking a key clinical milestone in advancing a potential disease-modifying therapy targeting beta-cell dysfunction.
Key Facts
- First patient dosed in COVALENT-211 and COVALENT-212, two Phase II trials of icovamenib in type 2 diabetes.
- COVALENT-211 targets insulin-deficient T2D patients; COVALENT-212 targets T2D patients uncontrolled on GLP-1 receptor agonists.
- Each trial will enroll ~60 patients (2:1 randomization), with primary endpoint at 26 weeks and durability assessed at 52 weeks.
- Topline data expected in Q4 2026.
- Prior Phase II COVALENT-111 data showed up to 1.5% and 1.8% placebo-adjusted HbA1c reductions in these subgroups, sustained for 9 months post-treatment.
Financial Impact
No direct financial impact from this announcement; clinical progress may enhance valuation potential ahead of data readouts.
Risk Factors
- Clinical trial delays or slow enrollment could push back data readouts.
- Phase II results may not replicate prior subgroup findings from COVALENT-111.
- Safety issues could emerge in larger or longer studies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3265295 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 8-K | $0.8340 $0.6901 | ▼ −17.25% | ▼ −17.71% | $0.6176 (−25.95%) |
Oct 13, 2026 13d ago | Press Release | $0.8340 $0.6901 | ▼ −17.25% | ▼ −17.71% | $0.6176 (−25.95%) |
Sep 23, 2026 4w ago | Press Release | $1.44 $1.33 | ▼ −7.64% | ▼ −6.96% | $0.6176 (−57.11%) |
Sep 22, 2026 4w ago | 424B5 | $1.44 $1.33 | ▲ +7.64% | ▲ +6.96% | $0.6176 (+57.11%) |
Sep 22, 2026 4w ago | Press Release | $1.44 $1.33 | ▲ +7.64% | ▲ +6.96% | $0.6176 (+57.11%) |
Jun 12, 2026 19w ago | Institutional Cluster | $1.17 $1.18 | ▲ +0.85% | ▲ +0.18% | $0.6176 (−47.21%) |
Jun 5, 2026 20w ago | Press Release | $1.15 $1.20 | ▲ +4.35% | ▲ +2.24% | $0.6176 (−46.30%) |
May 11, 2026 24w ago | 8-K | $1.58 $1.25 | ▼ −20.89% | ▼ −20.96% | $0.6176 (−60.91%) |
May 11, 2026 24w ago | Press Release | $1.58 $1.25 | ▼ −20.89% | ▼ −20.96% | $0.6176 (−60.91%) |
Apr 28, 2026 26w ago | 8-K | $1.53 $1.48 | ▼ −3.27% | ▼ −4.96% | $0.6176 (−59.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers